Bio-Techne (TECH) Cash & Equivalents (2009 - 2026)

Bio-Techne has reported Cash & Equivalents for 18 years, with the latest figure at $209.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 49.16% year-over-year to $209.8 million; the trailing twelve-month figure through Mar 2026 stood at $209.8 million (up 49.16% YoY), and the FY2025 full-year result was $162.2 million, up 6.85% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $209.8 million, up from $172.9 million in the prior quarter.
• The five-year high for Cash & Equivalents was $209.8 million in Q1 2026, with the low at $127.3 million in Q1 2023.
• Average Cash & Equivalents over 5 years is $161.0 million, with a median of $162.2 million recorded in 2025.
• Year-over-year, Cash & Equivalents slipped 22.7% in 2025 and jumped 49.16% in 2026.
• Tracing TECH's Cash & Equivalents over 5 years: stood at $164.7 million in 2022, then fell by 20.98% to $130.1 million in 2023, then soared by 36.44% to $177.5 million in 2024, then declined by 2.63% to $172.9 million in 2025, then advanced by 21.37% to $209.8 million in 2026.
• The last three Cash & Equivalents figures came in at $209.8 million (Q1 2026), $172.9 million (Q4 2025), and $145.0 million (Q3 2025), per Business Quant data.

Peer Comparison